Atomo Diagnostics released there Quarterly Activity Report Q2 FY22:

Highlights include:

• Increase in RAT test sales: Omicron variant, led to increasing demand for COVID-19 rapid antigen tests
• Cash receipts: quarterly cash receipts of $7.3m, H1 cash receipts in total $9.5m (PCP H1 FY21 of $5.8m).
• Revenue: Quarterly revenue from customers of $4.6m (full year FY21 was $6.7m)
• Debt free with $13.7m cash on hand

In addition, a further announcement was released stating the company has received approval to sell COVID-19 rapid antigen tests to NZ. This includes NZ District Health Board hospitals, Government agencies, the healthcare workforce, New Zealand-based businesses and pharmacies.

They have also announced 5 October 2021 that it had renegotiated its supply agreement with US manufacturer Access Bio providing the right, but not the obligation, for Atomo to purchase at a fixed price per unit up to 20 million COVID-19 rapid antigen tests (Atomo branded) during CY22 for sale in Australia and New Zealand.

Disc: not held

I need to do more research, I am not sure yet how potentially 20m rapid antigen tests translate into revenue/earning for FY22.

NOTE: Current market cap is $120m